Emerging Therapy Solutions welcomed Luke Prettol, CEBS, to the ETS Board of Directors to expand its work with self-funded employers and health care payers navigating cell and gene therapies and high-cost complex care.

Emerging Therapy Solutions® (ETS) helps self-insured employers, health plans, and secondary payers anticipate, navigate, and manage the growing complexity of cell and gene therapy (CGT) and transplants. As the only company solely focused on this rapidly evolving space, we combine more than 30 years of transplant and emerging therapy expertise with industry-leading clinical, financial, and operational guidance to help organizations stay ahead of what is next. Our comprehensive CGT360™ solution brings together predictive analytics, expert care navigation, and clinical support to help organizations manage every stage of the cell and gene therapy journey. Combined with our Centers of Excellence strategy, evidence-based medical policies, prior authorization support, and long-term planning expertise, ETS gives organizations the confidence to navigate one of healthcare's most complex and rapidly evolving markets. Hundreds of self-insured employers, health plans, brokers, consultants, stop-loss carriers, and reinsurance partners rely on ETS to make informed decisions, manage financial risk, and improve outcomes in one of healthcare's most dynamic and specialized fields.